The PACIFIC trial was a phase III study that evaluated PFS and OS with PD-L1 antibody durvalumab in patients with unresectable Stage III NSCLC that did not progress after concurrent chemoradiation therapy (CCRT). This evidence concerns the gene CD274 and non-small cell lung carcinoma.